Bronchodilators in cystic fibrosis: a critical analysis

References

• Doring G, Flume P, Heijerman H, et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11(6):461–479.
   PubMed Web of Science ®Google Scholar
• Heijerman H, Westerman E, Conway S, et al. consensus working g. inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2009;8(5):295–315.
   PubMed Web of Science ®Google Scholar
• Barry PJ, Ronan N, Plant BJ. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning. Semin Respir Crit Care Med. 2015;36(2):287–298.
   PubMed Web of Science ®Google Scholar
• Colombo JL. Long-acting bronchodilators in cystic fibrosis. Curr Opin Pulm Med. 2003;9(6):504–508.
   PubMed Web of Science ®Google Scholar
• Cropp GJ. Effectiveness of bronchodilators in cystic fibrosis. Am J Med. 1996;100(1A):19S–29S.
   Google Scholar
• Brand PL. Bronchodilators in cystic fibrosis. J R Soc Med. 2000;93(Suppl 38):37–39.
   PubMed Web of Science ®Google Scholar
• Orenstein DM. Long-term inhaled bronchodilator therapy in cystic fibrosis. Chest. 1991;99(5):1061.
   PubMed Web of Science ®Google Scholar
• Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957–969.
   PubMed Web of Science ®Google Scholar
• Mogayzel PJ Jr., Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–689.
   PubMed Web of Science ®Google Scholar
• Levine H, Cohen-Cymberknoh M, Klein N, et al. Reversible airway obstruction in cystic fibrosis: common, but not associated with characteristics of asthma. J Cyst Fibros. 2016;15:652–659.
   PubMed Web of Science ®Google Scholar
• Hordvik NL, Konig P, Morris D, et al. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis. 1985;131(6):889–893.
   PubMed Web of Science ®Google Scholar
• Kattan M, Mansell A, Levison H, et al. Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis. Thorax. 1980;35(7):531–535.
   PubMed Web of Science ®Google Scholar
• Sanchez I, Holbrow J, Chernick V. Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. J Pediatr. 1992;120(3):486–488.
   PubMed Web of Science ®Google Scholar
• Weintraub SJ, Eschenbacher WL. The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest. 1989;95(4):861–864.
   PubMed Web of Science ®Google Scholar
• Pattishall EN. Longitudinal response of pulmonary function to bronchodilators in cystic fibrosis. Pediatr Pulmonol. 1990;9(2):80–85.
   PubMed Web of Science ®Google Scholar
• Holzer FJ, Olinsky A, Phelan PD. Variability of airways hyper-reactivity and allergy in cystic fibrosis. Arch Dis Child. 1981;56(6):455–459.
   PubMed Web of Science ®Google Scholar
• Morgan WJ, Butler SM, Johnson CA, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol. 1999;28(4):231–241.
   PubMed Web of Science ®Google Scholar
• Koch C, McKenzie SG, Kaplowitz H, et al. International practice patterns by age and severity of lung disease in cystic fibrosis: data from the Epidemiologic Registry of Cystic Fibrosis (ERCF). Pediatr Pulmonol. 1997;24(2):147–154. discussion 159–161.
   PubMed Web of Science ®Google Scholar
• Balfour-Lynn IM, Elborn JS. “CF asthma”: what is it and what do we do about it? Thorax. 2002;57(8):742–748.
   PubMed Web of Science ®Google Scholar
• Kent BD, Lane SJ, van Beek EJ, et al. Asthma and cystic fibrosis: a tangled web. Pediatr Pulmonol. 2014;49(3):205–213.
   PubMed Web of Science ®Google Scholar
• Cunningham S, Prasad A, Collyer L, et al. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child. 2001;84(5):432–433.
   PubMed Web of Science ®Google Scholar
• Dodd ME, Abbott J, Maddison J, et al. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax. 1997;52(7):656–658.
   PubMed Web of Science ®Google Scholar
• Coates AL, MacNeish CF, Meisner D, et al. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest. 1997;111(5):1206–1212.
   PubMed Web of Science ®Google Scholar
• Nikolaizik WH, Jenni-Galovic V, Schoni MH. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Eur J Pediatr. 1996;155(7):608–611.
   PubMed Web of Science ®Google Scholar
• Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J. 2002;20(1):122–126.
   PubMed Web of Science ®Google Scholar
• Chua HL, Walker SL, LeSouef PN, et al. Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction. Pediatr Pulmonol. 1993;16(5):311–315.
   PubMed Web of Science ®Google Scholar
• Wong LB, Miller IF, Yeates DB. Stimulation of ciliary beat frequency by autonomic agonists: in vivo. J Appl Physiol (1985). 1988;65(2):971–981.
   PubMed Web of Science ®Google Scholar
• Bennett WD. Effect of beta-adrenergic agonists on mucociliary clearance. J Allergy Clin Immunol. 2002;110(6 Suppl):S291–297.
   Google Scholar
• Wood RE, Wanner A, Hirsch J, et al. Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline. Am Rev Respir Dis. 1975;111(6):733–738.
   PubMed Web of Science ®Google Scholar
• Mortensen J, Hansen A, Falk M, et al. Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest. 1993;103(3):805–811.
   PubMed Web of Science ®Google Scholar
• Taouil K, Hinnrasky J, Hologne C, et al. Stimulation of beta 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a cAMP/protein kinase A-independent pathway. J Biol Chem. 2003;278(19):17320–17327.
   PubMed Web of Science ®Google Scholar
• Delavoie F, Molinari M, Milliot M, et al. Salmeterol restores secretory functions in cystic fibrosis airway submucosal gland serous cells. Am J Respir Cell Mol Biol. 2009;40(4):388–397.
   PubMed Web of Science ®Google Scholar
• Vijftigschild LA, Berkers G, Dekkers JF, et al. beta2-adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis. Eur Respir J. 2016;48:768–779.
   PubMed Web of Science ®Google Scholar
• Zach MS, Oberwaldner B, Forche G, et al. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis. 1985;131(4):537–543.
   PubMed Web of Science ®Google Scholar
• Finnegan MJ, Hughes DV, Hodson ME. Comparison of nebulized and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis. Eur Respir J. 1992;5(9):1089–1091.
   PubMed Web of Science ®Google Scholar
• Avital A, Sanchez I, Chernick V. Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis. Pediatr Pulmonol. 1992;13(1):34–37.
   PubMed Web of Science ®Google Scholar
• Hordvik NL, Sammut PH, Judy CG, et al. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med. 1996;154(1):156–160.
   PubMed Web of Science ®Google Scholar
• Hordvik NL, Sammut PH, Judy CG, et al. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatr Pulmonol. 1999;27(1):43–53.
   PubMed Web of Science ®Google Scholar
• Ziebach R, Pietsch-Breitfeld B, Bichler M, et al. Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatr Pulmonol. 2001;31(6):431–435.
   PubMed Web of Science ®Google Scholar
• Dodd JD, Barry SC, Daly LE, et al. Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. J Cyst Fibros. 2005;4(2):101–105.
   PubMedGoogle Scholar
• Serisier DJ, Coates AD, Bowler SD. Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest. 2007;131(4):1181–1187.
   PubMed Web of Science ®Google Scholar
• Zinman R, Wohl ME, Ingram RH Jr. Nonhomogeneous lung emptying in cystic fibrosis patients. Volume history and bronchodilator effects. Am Rev Respir Dis. 1991;143(6):1257–1261.
   PubMed Web of Science ®Google Scholar
• Gustafsson PM. Peripheral airway involvement in CF and asthma compared by inert gas washout. Pediatr Pulmonol. 2007;42(2):168–176.
   PubMed Web of Science ®Google Scholar
• Eggleston PA, Rosenstein BJ, Stackhouse CM, et al. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest. 1991;99(5):1088–1092.
   PubMed Web of Science ®Google Scholar
• Konig P, Poehler J, Barbero GJ. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol. 1998;25(1):32–36.
   PubMed Web of Science ®Google Scholar
• Bargon J, Viel K, Dauletbaev N, et al. Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients. Eur Respir J. 1997;10(10):2307–2311.
   PubMed Web of Science ®Google Scholar
• Hordvik NL, Sammut PH, Judy CG, et al. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol. 2002;34(4):287–296.
   PubMed Web of Science ®Google Scholar
• Salvatore D, D’Andria M. Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatr Pulmonol. 2002;34(1):11–15.
   PubMed Web of Science ®Google Scholar
• Wiebicke W, Poynter A, Montgomery M, et al. [The effect of ipratropium bromide on lung function in patients with cystic fibrosis]. Pneumologie. 1990;44(Suppl 1):277–278.
   PubMedGoogle Scholar
• Sanchez I, De Koster J, Holbrow J, et al. The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. Chest. 1993;104(3):842–846.
   PubMed Web of Science ®Google Scholar
• Bradley JM, Koker P, Deng Q, et al. Testing two different doses of tiotropium respimat® in cystic fibrosis: phase 2 randomized trial results. PLoS One. 2014;9(9):e106195.
   Google Scholar
• Ratjen F, Koker P, Geller DE, et al. Tiotropium respimat in cystic fibrosis: phase 3 and pooled phase 2/3 randomized trials. J Cyst Fibros. 2015;14(5):608–614.
   PubMed Web of Science ®Google Scholar
• Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013;68(4):344–350.
   PubMed Web of Science ®Google Scholar
• Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros. 2011;10(1):54–61.
   PubMed Web of Science ®Google Scholar
• Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91–96.
   PubMed Web of Science ®Google Scholar
• Daniels T, Goodacre L, Sutton C, et al. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest. 2011;140(2):425–432.
   PubMed Web of Science ®Google Scholar